drugset / Trial / NCT03722407
Ruxolitinib for the Treatment of Chronic Myelomonocytic Leukemia (CMML): A Phase 2 Expansion
Phase 2
Active not recruiting
29 enrolled
H. Lee Moffitt Cancer Center and Research Institute
Incyte Corporation · collab
NaSequentialOpen-labelTreatment
Summary
This study is to find out if treating Chronic Myelomonocytic Leukemia (CMML) with a study drug (ruxolitinib) can improve outcomes of patients with CMML.
Timeline
- Start
- 2019-08-28
- Primary completion
- 2022-09-19
- Completion
- 2027-05-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ruxolitinib | Small molecule | 40 mg | Oral |